A major contributor to this expansion is the rising incidence of multiple sclerosis (MS), along with other related disorders such as neuromyelitis optica (NMO), acute disseminated encephalomyelitis ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

MILAN — Treatment of rheumatoid arthritis (RA) with tumor necrosis factor inhibitors (TNFi) does not appear to demonstrate a consistent and significant risk for demyelinating disease, according to a ...

The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. In patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP ...

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct diagnosis.

A recent study aimed to evaluate the burden of age of onset of cardiovascular conditions in a US population with multiple sclerosis, neuromyelitis optica spectrum disorder, or transverse myelitis and ...

PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

The SC formulation of efgartigimod alfa plus hyaluronidase-qvfc is currently marketed under the trade name Vyvgart Hytrulo and is approved for the treatment of generalized myasthenia gravis. The Food ...

Teriflunomide treatment incurred an unadjusted risk reduction of 63% and an adjusted risk reduction of 72% in inhibiting a first clinical demyelinating event in patients with multiple sclerosis (MS).

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.